CDKN2A anticorps (C-Term)

N° du produit ABIN1981278

Détail du produit anti-CDKN2A anticorps

Antigène: CDKN2A (Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) (CDKN2A))

Épitope: AA 104-131, C-Term

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp CDKN2A est non-conjugé

Application: Western Blotting (WB), Immunofluorescence (IF), Flow Cytometry (FACS), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Purification: This antibody is purified through a protein A column, followed by peptide affinity purification.

Immunogène: This p16INK4a antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 104-131 amino acids from the C-terminal region of human p16INK4a.

Clone: RB19093

Isotype: Ig Fraction

Information d'application

Indications d'application: IF: 1:10~50. WB: 1:2000. WB: 1:2000. IHC-P-Leica: 1:500. FC: 1:25

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Stockage commentaire: Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Date de péremption: 6 months

Références pour anticorps anti-CDKN2A (ABIN1981278)

Han, Li, Zhang, Qin, Yang, Wang, Yuan, Xia: "Brain lipid-binding protein promotes proliferation and modulates cell cycle in C6 rat glioma cells." dans: International journal of oncology, Vol. 51, Issue 5, pp. 1439-1448, (2018) (PubMed).

Détails sur CDKN2A

Antigène: CDKN2A (Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) (CDKN2A))

Autre désignation: p16INK4a (CDKN2A Produits)

Synonymes: anticorps Arf, anticorps p16, anticorps MTS1, anticorps INK4A, anticorps p19ARF, anticorps p16Cdkn2a, anticorps ARF, anticorps CDK4I, anticorps CDKN2, anticorps CMM2, anticorps INK4, anticorps MLM, anticorps MTS-1, anticorps P14, anticorps P14ARF, anticorps P16, anticorps P16-INK4A, anticorps P16INK4, anticorps P16INK4A, anticorps P19, anticorps P19ARF, anticorps TP16, anticorps ARF-INK4a, anticorps INK4a-ARF, anticorps Ink4a/Arf, anticorps Pctr1, anticorps p16(INK4a), anticorps p16INK4a, anticorps p19, anticorps cyclin-dependent kinase inhibitor 2A, anticorps cyclin dependent kinase inhibitor 2A, anticorps Cdkn2a, anticorps LOC100731972, anticorps LOC100340625, anticorps CDKN2A

Sujet: This gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene, this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, MDM1, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene.

Poids moléculaire: 16533

ID gène: 1029

NCBI Accession: NP_000068, NP_001182061, NP_478104

UniProt: P42771

Pathways: Mitotic G1-G1/S Phases, Stem Cell Maintenance, Positive Regulation of Endopeptidase Activity, Autophagy, Positive Regulation of Response to DNA Damage Stimulus